News und Analysen
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces measures to prioritize resource allocation in its Sample to Insight Portfolio
DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an
DGAP-Adhoc: QIAGEN N.V.: QIAGEN kündigt Maßnahmen zur Priorisierung von Ressourcen für das 'Sample to Insight' Portfolio an
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
EQS-News: Evotec announces change in Management Board
EQS-News: Evotec announces change in Management Board
EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
EQS-News: Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
EQS-News: Evotec SE reports H1 2024 results: Challenging year; priority reset for sustainable profitable growth gaining momentum, building on core strengths
EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces strong progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec SE reports first half-year 2024 results on 14 August 2024
EQS-News: Evotec SE reports first half-year 2024 results on 14 August 2024
EQS-News: Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue
EQS-News: Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
EQS-News: MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-News: Half-year results: Moderately positive revenue development in the second quarter; demand recovery remains muted, full-year outlook deliberately more cautious; long-term trends remain positive
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
EQS-Adhoc: Sartorius AG adjusts its guidance for fiscal year 2024 and presents results for H1 2024
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-News: MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-Adhoc: Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
EQS-Adhoc: Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business
EQS-Adhoc: Carl Zeiss Meditec AG: Revenue and EBIT forecast for fiscal year 2023/24 reduced amid slower than expected recovery of equipment business